Arcutis Biotherapeutics, Inc. (ARQT) — Stock Score Summary

Arcutis Biotherapeutics, Inc. (ARQT) has a MoatMap StockRank of 24/100 based on Quality (51/100), Value (14/100), and Momentum (46/100) factor scores. The current signal is SELL. Arcutis Biotherapeutics is a commercial-stage biopharma company with negative cash flows and high SG&A expenses. It does not possess the structural profitability or reinvestment runway of a Terry Smith-style compounder.

Arcutis Biotherapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing innovative treatments for immune-mediated dermatological diseases, with its lead product, Zoryve, for plaque psoriasis. Its competitive moat is a proprietary drug development platform targeting specific disease pathways in dermatology, offering novel therapeutic options with strong intellectual property. Arcutis is a specialized biopharma company focused on dermatological innovation, transitioning to a commercial-stage entity with an approved product and robust pipeline.

Key Financial Metrics

Price$21.26
Market Cap$2.7B
P/E (Forward)18.99
Price/Book14.47
Return on Equity-1.4%
Return on Invested Capital-1.0%
Debt/Equity60.47
Gross Margin90.9%
Operating Margin-8.6%
Revenue Growth60.1%
Free Cash Flow$4M

Arcutis Biotherapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Arcutis Biotherapeutics, Inc.’s (ARQT) StockRank?
MoatMap’s StockRank for Arcutis Biotherapeutics, Inc. (ARQT) is 24/100, with a Sell signal. It is a composite of Quality (51), Value (14), and Momentum (46) factor ranks across MoatMap’s 19,000+ stock universe.
Does Arcutis Biotherapeutics, Inc. have an economic moat?
Arcutis Biotherapeutics, Inc. (ARQT) has a Quality factor score of 51/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Arcutis Biotherapeutics, Inc. a buy, hold, or sell?
MoatMap’s current signal for Arcutis Biotherapeutics, Inc. (ARQT) is Sell, based on a StockRank of 24/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Arcutis Biotherapeutics, Inc. in?
Arcutis Biotherapeutics, Inc. (ARQT) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksARQT deep dive reportAI ChampionsHow we score stocksSense-check another stock